BRPI0415853A - sal de cloridreto de telavancina, processo para preparar um sal de cloridreto de telavancina e produto - Google Patents

sal de cloridreto de telavancina, processo para preparar um sal de cloridreto de telavancina e produto

Info

Publication number
BRPI0415853A
BRPI0415853A BRPI0415853-9A BRPI0415853A BRPI0415853A BR PI0415853 A BRPI0415853 A BR PI0415853A BR PI0415853 A BRPI0415853 A BR PI0415853A BR PI0415853 A BRPI0415853 A BR PI0415853A
Authority
BR
Brazil
Prior art keywords
hydrochloride salt
preparing
telavancin
telavancin hydrochloride
product
Prior art date
Application number
BRPI0415853-9A
Other languages
English (en)
Inventor
Jyanwei Liu
Junning Lee
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of BRPI0415853A publication Critical patent/BRPI0415853A/pt
Publication of BRPI0415853B1 publication Critical patent/BRPI0415853B1/pt
Publication of BRPI0415853B8 publication Critical patent/BRPI0415853B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"SAL DE CLORIDRETO DE TELAVANCINA, PROCESSO PARA PREPARAR UM SAL DE CLORIDRETO DE TELAVANCINA E PRODUTO". Revelados são sais de cloridreto de telavancina tendo um teor de íon cloreto de cerca de 2,4% em peso a cerca de 4,8% em peso. Os sais revelados têm estabilidade melhorada durante armazenamento em temperatura ambientes comparados com outros sais de cloridreto. Também revelados são processos para preparar tais sais.
BRPI0415853A 2003-10-22 2004-10-21 processo para preparar um sal de cloridrato de telavancina BRPI0415853B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51335903P 2003-10-22 2003-10-22
US60/513.359 2003-10-22
PCT/US2004/034958 WO2005042568A2 (en) 2003-10-22 2004-10-21 Hydrochloride salts of a glycopeptide phosphonate derivative

Publications (3)

Publication Number Publication Date
BRPI0415853A true BRPI0415853A (pt) 2007-01-02
BRPI0415853B1 BRPI0415853B1 (pt) 2017-12-12
BRPI0415853B8 BRPI0415853B8 (pt) 2021-05-25

Family

ID=34549267

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415853A BRPI0415853B8 (pt) 2003-10-22 2004-10-21 processo para preparar um sal de cloridrato de telavancina

Country Status (18)

Country Link
US (2) US7531623B2 (pt)
EP (2) EP2495251B1 (pt)
JP (2) JP4669478B2 (pt)
KR (2) KR20120037025A (pt)
CN (1) CN100417661C (pt)
AU (1) AU2004285924B2 (pt)
BR (1) BRPI0415853B8 (pt)
CA (2) CA2543009C (pt)
DK (2) DK1678201T3 (pt)
ES (2) ES2400483T3 (pt)
HK (2) HK1093516A1 (pt)
HU (1) HUE026769T2 (pt)
MX (1) MXPA06004336A (pt)
PL (2) PL1678201T3 (pt)
PT (2) PT2495251E (pt)
SI (2) SI1678201T1 (pt)
TW (1) TWI342312B (pt)
WO (1) WO2005042568A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
EP3693017A1 (en) 2010-12-14 2020-08-12 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
BR112015022716A2 (pt) 2013-03-13 2017-07-18 Theravance Biopharma Antibiotics Ip Llc sais de cloridrato de um composto antibiótico
TN2017000358A1 (en) * 2015-02-23 2019-01-16 Theravance Biopharma Antibiotics Ip Llc Doses and methods of administering telavancin
CN104877014B (zh) * 2015-06-02 2018-05-11 宁夏泰瑞制药股份有限公司 一种纯化特拉万星粗品的方法
CN106631902A (zh) * 2016-09-23 2017-05-10 上海步越化工科技有限公司 一种特拉万星侧链癸基(2‑氧代乙基)氨基甲酸9h‑芴‑9‑甲基酯的制备方法
CA3062570A1 (en) 2017-05-22 2018-11-29 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof
CN107629116B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107629115B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN110824079B (zh) * 2019-11-27 2021-04-13 苏州赛分科技有限公司 特拉万星的纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067099A (en) 1955-09-16 1962-12-04 Lilly Co Eli Vancomycin and method for its preparation
US4885275A (en) 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
WO1999017793A1 (fr) 1997-10-03 1999-04-15 Fujisawa Pharmaceutical Co., Ltd. Chlorhydrates de vancomycines antibiotiques et leur procede de production
BR0110530A (pt) 2000-05-02 2003-04-08 Theravance Inc Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
TWI233932B (en) 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
TWI275594B (en) 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI312785B (en) 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI342312B (en) 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative

Also Published As

Publication number Publication date
US7531623B2 (en) 2009-05-12
CN100417661C (zh) 2008-09-10
ES2400483T3 (es) 2013-04-10
PL1678201T3 (pl) 2013-05-31
TWI342312B (en) 2011-05-21
EP1678201B1 (en) 2012-12-05
BRPI0415853B8 (pt) 2021-05-25
EP2495251B1 (en) 2014-04-16
ES2477268T3 (es) 2014-07-16
DK2495251T3 (da) 2014-07-07
JP2011016820A (ja) 2011-01-27
CA2543009C (en) 2011-01-11
HK1093516A1 (en) 2007-03-02
AU2004285924A1 (en) 2005-05-12
PT2495251E (pt) 2014-07-11
US8003755B2 (en) 2011-08-23
CN1871253A (zh) 2006-11-29
KR101166250B1 (ko) 2012-07-17
BRPI0415853B1 (pt) 2017-12-12
JP4669478B2 (ja) 2011-04-13
CA2543009A1 (en) 2005-05-12
PL2495251T3 (pl) 2014-09-30
AU2004285924B2 (en) 2011-02-24
US20050113561A1 (en) 2005-05-26
CA2726967A1 (en) 2005-05-12
US20090069534A1 (en) 2009-03-12
EP1678201A2 (en) 2006-07-12
JP2007534630A (ja) 2007-11-29
SI2495251T1 (sl) 2014-07-31
HK1171030A1 (en) 2013-03-15
PT1678201E (pt) 2013-03-05
DK1678201T3 (da) 2013-03-04
WO2005042568A2 (en) 2005-05-12
EP2495251A1 (en) 2012-09-05
KR20120037025A (ko) 2012-04-18
SI1678201T1 (sl) 2013-03-29
HUE026769T2 (hu) 2016-07-28
KR20060094082A (ko) 2006-08-28
TW200528473A (en) 2005-09-01
WO2005042568A3 (en) 2005-09-15
MXPA06004336A (es) 2006-06-27

Similar Documents

Publication Publication Date Title
BR0211313A (pt) Misturas de biocidas contendo halogênio, estabilizantes de halogênio e biocidas contendo nitrogênio
BR9407047A (pt) Processo para separaçao de uma proteina de uma soluçao aquosa de proteinas
BRPI0416143A (pt) sais farmaceuticamente aceitáveis de compostos de quinolinona tendo propriedades farmacêuticas aperfeiçoadas
BRPI0417813A (pt) composto, processo para preparar o mesmo, agente, processos para preparar o mesmo, e para combater vegetação indesejada, e, uso de compostos
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA200400432A1 (ru) Производные мочевины
BR0201437A (pt) Processo para preparar derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituìdos"
BRPI0415853A (pt) sal de cloridreto de telavancina, processo para preparar um sal de cloridreto de telavancina e produto
BRPI0517916B8 (pt) comprimido compreendendo carbonato de sevelamer e cloreto de sódio, e, uso de um comprimido
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
BR0309933A (pt) (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetraidrofurilc arbonil)-4-piperidinil-metil]-4-piperidinil] benzamida, processo para sua preparação, composição farmacêutica contendo o mesmo e intermediários obtidos desta forma
BR0307782A (pt) Compostos azabiciclo para o tratamento de doença
BR9914998A (pt) Antibióticos macrólidos
BR9908702A (pt) Composto, processos para inibir sìntese de óxido nìtrico em um paciente, para inibir seletivamente sìntese de óxido nìtrico produzido pela no sintase indutìvel no óxido nìtrico produzido pelas formas constitutivas de no sintase em um paciente e para diminuir nìveis de óxido nìtrico em um paciente, e, composição farmacêutica
ATE282610T1 (de) Heterozyklische verbindungen mit faktor xa hemmender wirkung
BR0008112A (pt) Agonistas de 5-ht 1f
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3
EA200500701A1 (ru) Новая кристаллическая форма натриевой соли 3-пиридил-1-гидроксиэтилиден-1,1-бисфосфоновой кислоты
BR0215067A (pt) Piridoquinoxalinas antivirais
PT854724E (pt) Metodo de tratar a doenca navicular em cavalos
DE602004011921D1 (de) Verfahren zur herstellung von (4-hydroxy-6-oxo-tetrahydropyran-2-yl) acetonitril und dessen derivaten
SE9403831D0 (sv) A storage stable water solution for infusion I
BRPI0409564A (pt) sistema estabilizador para polìmeros halogenados
IT1301993B1 (it) Processo per la preparazione di zofenopril sale di calcio.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/12/2017, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2693 DE 16-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.